Introduction
Super-refractory status epilepticus (SE) is characterized by unresponsiveness to initial anaesthetic therapy. This definition encompasses a SE that continues or recurs 24 h or more after the onset of anaesthetic therapy and includes those cases in which SE recurs on the reduction or withdrawal of anaesthesia. Treatment is difficult due to the failure of first-and second-line therapy. As no controlled or randomized studies are available on this phenomenon, further therapeutic management is based on clinical reports and expert opinion. 1 The ketogenic diet (KD) is a high-fat, low-carbohydrate and adequate protein diet that has been an established, effective nonpharmacological treatment in the management of refractory epilepsy and severe childhood encephalopathies since the early 1920s. The KD alters the primary cerebral energy metabolism from glucose to ketone bodies and probably has multiple mechanisms of antiepileptic action. 2 Emergency use of KD has been reported predominantly in children with SE. 3, 4 In adults only five case reports on prolonged SE have been published. [5] [6] [7] [8] The KD should probably be tried in all severe cases of super-refractory SE. 1 Patients usually receive a commercial enteral KD preparation (4:1 or 3:1 ketogenic ratio: grams of fat to protein and carbohydrates combined), which is usually administered via a gastric or gastrostomy tube, provided the patient tolerates tube feeds well.
We report a case in which a KD was started intravenously leading to subsequent ketosis in an adult patient with superrefractory status epilepticus and intestinal dysmotility.
Case report
This female patient initially presented at the age of 14 years with myoclonus and generalized tonic-clonic seizures. Over the previous 7 years no seizure remission had been achieved on various combinations of anticonvulsant drugs or treatment with vagus nerve stimulation. Furthermore, disturbance in gait (ataxia) and cognitive decline were rapidly progressing. Subsequently a mutation in the EPM2A gene and thus a diagnosis of Lafora disease was established.
At the age of 21 years she presented with a generalized, convulsive SE. At admission the anticonvulsive regimen was valproate 780 mg/d, levetiracetam 4000 mg/d, topiramate 250 mg/ d and clonazepam 9 mg/d (Fig. 1a) . The treatment of SE required generalized anaesthesia with propofol (200 mg/h), which had to be discontinued due to 8II atrioventricular block. Adequate sedation could not be achieved with midazolam (100 mg/h) and finally thiopental (500 mg/h) anaesthesia was established for 48 h. Over the next 15 days, she continued to have frequent myoclonic and generalized tonic-clonic seizures without recovery to baseline mental status. Multiple routine EEGs showed periodic generalized epileptiform discharges pointing to the diagnosis of ongoing SE (Fig. 1b) . The anticonvulsive regimen was switched to valproate 960 mg/d, levetiracetam 4000 mg/d, zonisamide 600 mg/d, piracetam 7000 mg/d and clonazepam 9 mg/d. On hospital day 7, treatment with steroids over 5 days (methylprednisolone 1000 mg/d) was started and magnesium was added on hospital day 15 without resolution of SE. Magnesium had to be discontinued after 8 h due to reoccurrence of 8II atrioventricular block. On hospital day 16 the patient went into another generalized, convulsive SE that could not be controlled with midazolam up to 250 mg/h. Again thiopental (500 mg/h) anaesthesia was established for 48 h.
Intravenous emergency ketogenic diet induction
Upon infusion of thiopental, parenteral nutrition was stopped and a fasting period of 6 h was started in preparation for emergency induction of a KD. As the patient did not tolerate tube feeds and had prominent reflux intravenous administration of KD was preferred. The patient received a KD with 1000 kcal during the first 24 h and 1500 kcal/d on the following days according to Table 1 . The KD was infused continuously over 16 h and was stopped for 8 h at nighttime. Glucose-free solutions such as saline were also given as required. The KD had a 4:1 ketogenic ratio and was composed of commercially available fat emulsion with medium-chain triglycerides (Lipofundin 20% with MCT, B. Braun Melsungen, Germany), amino acid (Aminoplasmal 10%, B. Braun Melsungen, Germany) and carbohydrate (Glucose 5%, B. Braun Melsungen, Germany) solutions for intravenous application. There was no hypoglycaemia or acidosis upon starting the KD. Urine ketones were detected (urine stix: +) after 3.5 days and persisted at high concentrations from day 4 onwards (urine stix: ++++). Ketone bodies were confirmed in the plasma with a b-hydroxybutyrate level of 3627 mmol/l and acetoacetate of 1705 mmol/l. Parenteral administration of KD was continued until hospital day 27 and then switched to an enteral preparation administered via gastrostomy tube. The commercially available KetoCal 4:1 LQ Multi Fibre 237 ml (Nutricia GmbH, Heilbronn, Germany) was given 5 times per day resulting in a total daily intake of 1780 kcal. Subsequently the patient and EEG (Fig. 1c) improved. Her mental status gradually recovered to baseline. She continued to have daily myoclonus, and generalized tonic-clonic seizures occurred every 3-4 days. On hospital day 47 she was discharged and no further episodes of status epilepticus were reported during the 4-month follow-up.
Discussion
We report a case treated with a total parenteral KD and subsequent ketosis in super-refractory SE. Initiation of KD resolved the SE, which was refractory to multiple anticonvulsants, anaesthetics, steroids and magnesium. To the best of our knowledge, this is the first reported case of intravenous KD for the treatment of SE. Administration of KD was safe and feasible with commercially available fat emulsion containing mediumchain triglycerides as well as amino acid and carbohydrate solutions. Ketosis was achieved within 3.5 days and was maintained for a further 6 days via the intravenous route of administration. We did not observe any hypoglycaemia, acidosis or any other complications. However, the relationship between the KD and resolution of SE is not absolutely certain given the considerable amount of confounding factors.
A retrospective study 9 reported on the successful maintenance of ketosis using ketogenic parenteral nutrition in 10 children with intractable epilepsy who required bowel rest due to vomiting, severe diarrhoea, intolerability of a nasogastric tube or intestinal bleeding. The mean duration of the ketogenic parenteral nutrition was 4.1 days and it could be successfully changed back to enteral KD later on. The authors used conventional intravenous fat emulsion (20% Lipision, long-chain triglyceride) plus dextrose and amino acid (6% TrophAmine) hyperalimentation available in South Korea. 9 The preparation of parenteral KD should be feasible everywhere with commercially available, standard intravenous solutions. Larger studies are warranted to better understand the efficacy and tolerability of parental KD, and its potential use in SE. Parenteral KD proved to be a relatively safe short-term method in our adult case and in the reported study on children. 9 In conclusion, our case suggests that parenteral initiation of ketosis can be successfully implemented in critically ill patients and might simplify access to this treatment alternative in superrefractory status epilepticus. We confirm that we have read Seizure's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. Table 1 Total parenteral ketogenic diet (ratio 4:1).
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